Militia Capital Partners LP Invests $1.82 Million in Teva Pharmaceutical Industries Ltd. $TEVA

Militia Capital Partners LP acquired a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 90,000 shares of the company’s stock, valued at approximately $1,818,000. Teva Pharmaceutical Industries makes up 0.9% of Militia Capital Partners LP’s investment portfolio, making the stock its 28th largest position.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Advisors Asset Management Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the second quarter valued at $41,000. Cromwell Holdings LLC boosted its position in shares of Teva Pharmaceutical Industries by 40.3% in the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after buying an additional 629 shares in the last quarter. MAI Capital Management grew its stake in Teva Pharmaceutical Industries by 26.8% in the 2nd quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after acquiring an additional 697 shares during the last quarter. Rothschild Investment LLC grew its stake in Teva Pharmaceutical Industries by 97.0% in the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock valued at $55,000 after acquiring an additional 1,348 shares during the last quarter. Finally, JFS Wealth Advisors LLC increased its holdings in Teva Pharmaceutical Industries by 257.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock valued at $56,000 after acquiring an additional 2,000 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Placid Jover sold 14,150 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $448,130.50. Following the completion of the transaction, the insider directly owned 6,774 shares in the company, valued at approximately $214,532.58. This represents a 67.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Christine Fox sold 7,924 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $250,953.08. Following the transaction, the executive vice president owned 84,905 shares in the company, valued at $2,688,941.35. This trade represents a 8.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 858,799 shares of company stock valued at $28,185,035. 0.55% of the stock is currently owned by company insiders.

Analyst Ratings Changes

TEVA has been the topic of several recent research reports. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. Piper Sandler restated an “overweight” rating and set a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, March 4th. Truist Financial upped their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Bank of America increased their target price on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Finally, Barclays boosted their price target on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a report on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.67.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $29.47 on Tuesday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. The company has a market capitalization of $33.88 billion, a price-to-earnings ratio of 24.56, a PEG ratio of 9.56 and a beta of 0.72. The company’s 50 day simple moving average is $32.88 and its 200 day simple moving average is $26.82. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.65 by $0.31. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. Teva Pharmaceutical Industries’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.